📊 APYX Key Takeaways
Is Apyx Medical Corp (APYX) a Good Investment?
Apyx Medical is a financially distressed company with deteriorating fundamentals, burning cash while unable to generate operating profitability. Despite holding a strong cash position of $31.7M, the company faces a critical solvency issue with $37.5M in long-term debt and negative free cash flow of -$9.1M, which will deplete reserves rapidly at current burn rates. The combination of flat revenue growth, -21.2% net margins, negative ROE of -77.1%, and persistent operating losses indicates fundamental business model challenges that require immediate restructuring.
Apyx Medical shows decent gross profitability and strong near-term liquidity, but those positives are outweighed by flat revenue, persistent operating losses, and negative free cash flow. The balance sheet is pressured by high leverage relative to a small equity base, and negative interest coverage suggests the current capital structure is not being supported by operating earnings.
Why Buy Apyx Medical Corp Stock? APYX Key Strengths
- Strong gross margins at 62.5% indicate healthy product economics and pricing power
- Adequate current ratio of 5.00x and quick ratio of 4.26x provide near-term liquidity cushion
- Modest asset base of $66.8M limits downside exposure compared to larger medtech peers
- Gross margin of 62.5% indicates the core product mix still has solid unit economics
- Cash of $31.74M and a 5.00x current ratio provide meaningful near-term liquidity
- Capital expenditure needs are modest, which limits the cash burden from reinvestment
APYX Stock Risks: Apyx Medical Corp Investment Risks
- Critical cash burn: -$9.1M free cash flow will exhaust $31.7M cash position in ~3.5 years at current rate
- Unsustainable leverage: $37.5M long-term debt against $14.5M equity (2.58x debt-to-equity) with negative interest coverage of -2.3x
- Revenue stagnation and severe operating losses: 0% YoY revenue growth with -$6.4M operating income indicates inability to scale profitably
- Deteriorating equity position: -77.1% ROE and -16.8% ROA demonstrate value destruction for shareholders
- Structural unprofitability: -21.2% net margin unsustainable for long-term viability
- Revenue is flat, raising concern that losses are not being fixed through scale or operating leverage
- Net margin of -21.2% and operating margin of -12.2% show the business remains structurally unprofitable
- Debt-to-equity of 2.58x and negative interest coverage create refinancing and balance-sheet risk if losses persist
Key Metrics to Watch
- Operating cash flow trajectory - must turn positive within 12-18 months
- Gross margin sustainability - any decline below 60% indicates competitive pressure
- Debt reduction progress - refinancing or debt restructuring required before cash depletion
- Revenue growth acceleration - must achieve 15%+ growth to reach operating profitability
- Operating margin path to breakeven - critical inflection point for viability
- Revenue growth acceleration versus continued flat sales
- Operating cash flow improvement toward sustained break-even
Apyx Medical Corp (APYX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.00x current ratio provides a solid financial cushion.
APYX Profit Margin, ROE & Profitability Analysis
APYX vs Healthcare Sector: How Apyx Medical Corp Compares
How Apyx Medical Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Apyx Medical Corp Stock Overvalued? APYX Valuation Analysis 2026
Based on fundamental analysis, Apyx Medical Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Apyx Medical Corp Balance Sheet: APYX Debt, Cash & Liquidity
APYX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Apyx Medical Corp's revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $-0.67 indicates the company is currently unprofitable.
APYX Revenue Growth, EPS Growth & YoY Performance
APYX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.5M | -$2.0M | N/A |
| Q2 2025 | $11.4M | -$3.8M | N/A |
| Q1 2025 | $9.4M | -$4.2M | N/A |
| Q3 2024 | $11.5M | -$4.6M | N/A |
| Q2 2024 | $12.1M | -$994.0K | $-0.03 |
| Q1 2024 | $10.2M | -$3.5M | $-0.10 |
| Q3 2023 | $9.1M | -$4.6M | $-0.13 |
| Q2 2023 | $10.3M | -$994.0K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Apyx Medical Corp Dividends, Buybacks & Capital Allocation
APYX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Apyx Medical Corp (CIK: 0000719135)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APYX
What is the AI rating for APYX?
Apyx Medical Corp (APYX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APYX's key strengths?
Claude: Strong gross margins at 62.5% indicate healthy product economics and pricing power. Adequate current ratio of 5.00x and quick ratio of 4.26x provide near-term liquidity cushion. ChatGPT: Gross margin of 62.5% indicates the core product mix still has solid unit economics. Cash of $31.74M and a 5.00x current ratio provide meaningful near-term liquidity.
What are the risks of investing in APYX?
Claude: Critical cash burn: -$9.1M free cash flow will exhaust $31.7M cash position in ~3.5 years at current rate. Unsustainable leverage: $37.5M long-term debt against $14.5M equity (2.58x debt-to-equity) with negative interest coverage of -2.3x. ChatGPT: Revenue is flat, raising concern that losses are not being fixed through scale or operating leverage. Net margin of -21.2% and operating margin of -12.2% show the business remains structurally unprofitable.
What is APYX's revenue and growth?
Apyx Medical Corp reported revenue of $52.8M.
Does APYX pay dividends?
Apyx Medical Corp does not currently pay dividends.
Where can I find APYX SEC filings?
Official SEC filings for Apyx Medical Corp (CIK: 0000719135) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APYX's EPS?
Apyx Medical Corp has a diluted EPS of $-0.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APYX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Apyx Medical Corp has a SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APYX stock overvalued or undervalued?
Valuation metrics for APYX: ROE of -77.1% (sector avg: 15%), net margin of -21.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APYX stock in 2026?
Our dual AI analysis gives Apyx Medical Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APYX's free cash flow?
Apyx Medical Corp's operating cash flow is $-8.0M, with capital expenditures of $1.1M. FCF margin is -17.2%.
How does APYX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -21.2% (avg: 12%), ROE -77.1% (avg: 15%), current ratio 5.00 (avg: 2).
Is Apyx Medical Corp carrying too much debt?
APYX has a debt-to-equity ratio of 2.58x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 5.00 suggests adequate short-term liquidity.